P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

Noxafil Delayed-Release Tablets Approved

New formulation for prevention of Aspergillus and Candida infections (November 26)

A new formulation for posaconazole (Noxafil, Merck) 100 mg delayed-release tablets has been approved. Patients take a loading dose of 300 mg (three 100-mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100-mg delayed-release tablets) starting on the second day of therapy.

Merck also sells a 40-mg/mL oral suspension, which is taken three times daily.

The delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older with a severely compromised immune system, such as hematopoietic stem-cell transplant recipients with graft-versus-host disease or those with hematological malignancies with prolonged neutropenia resulting from chemotherapy.

Posaconazole delayed-release tablets and the oral suspension are not to be used interchangeably because of differences in the dosing of each formulation.

[Source: Merck; November 26, 2013.]

More stories